These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 27036386)

  • 21. Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis.
    Stamp L; Morillon MB; Taylor WJ; Dalbeth N; Singh JA; Lassere M; Christensen R
    Semin Arthritis Rheum; 2018 Oct; 48(2):293-301. PubMed ID: 29566967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Topless R; Noorbaloochi S; Merriman TR; Singh JA
    Semin Arthritis Rheum; 2022 Oct; 56():152057. PubMed ID: 35835008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating appropriate use of prophylactic colchicine for gout flare prevention.
    George M; Pullman-Mooar S; Hussain F; Schumacher HR
    Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1258-62. PubMed ID: 24376081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
    Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
    Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flares.
    Russell MD; Ameyaw-Kyeremeh L; Dell'Accio F; Lapham H; Head N; Stovin C; Patel V; Clarke BD; Nagra D; Alveyn E; Adas MA; Bechman K; de la Puente MA; Ellis B; Byrne C; Patel R; Rutherford AI; Cantle F; Norton S; Roddy E; Hudson J; Cope AP; Galloway JB
    Rheumatology (Oxford); 2024 Aug; 63(8):2222-2229. PubMed ID: 37929968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are Target Urate and Remission Possible in Severe Gout? A Five-year Cohort Study.
    Alvarado-de la Barrera C; López-López CO; Álvarez-Hernández E; Peláez-Ballestas I; Gómez-Ruiz C; Burgos-Vargas R; Vázquez-Mellado J
    J Rheumatol; 2020 Jan; 47(1):132-139. PubMed ID: 31043541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study.
    Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Perez-Ruiz F; Hammer HB
    Clin Rheumatol; 2022 Dec; 41(12):3817-3823. PubMed ID: 36316609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Casebook consults: improving outcomes in gout (multimedia activity).
    Doghramji PP; Mandell BF; Pope RS
    Am J Med; 2012 Aug; 125(8):S1. PubMed ID: 22840678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urate-lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink.
    Kiddle SJ; Sundell KA; Perl S; Nolan S; Bjursell M
    Clin Cardiol; 2024 Jun; 47(6):e24297. PubMed ID: 38873862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First validation of the gout activity score against gout impact scale in a primary care based gout cohort.
    La-Crette J; Jenkins W; Fernandes G; Valdes AM; Doherty M; Abhishek A
    Joint Bone Spine; 2018 May; 85(3):323-325. PubMed ID: 28528279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target.
    Uhlig T; Karoliussen LF; Sexton J; Borgen T; Haavardsholm EA; Kvien TK; Hammer HB
    RMD Open; 2021 Mar; 7(1):. PubMed ID: 33782189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in France.
    Samp JC; Perry R; Piercy J; Wood R; Baran RW
    Clin Res Hepatol Gastroenterol; 2015 Jun; 39(3):307-14. PubMed ID: 25511922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout.
    Richardson JC; Liddle J; Mallen CD; Roddy E; Hider S; Prinjha S; Ziebland S
    BMC Musculoskelet Disord; 2016 Jun; 17():249. PubMed ID: 27267878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study.
    Abhishek A; Jenkins W; La-Crette J; Fernandes G; Doherty M
    Rheumatology (Oxford); 2017 Apr; 56(4):529-533. PubMed ID: 28082620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
    Bakris GL; Doghramji PP; Keenan RT; Silber SH
    Am J Med; 2014 Jan; 127(1):S1. PubMed ID: 24268074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.
    Sundy JS; Schumacher HR; Kivitz A; Weinstein SP; Wu R; King-Davis S; Evans RR
    J Rheumatol; 2014 Aug; 41(8):1703-11. PubMed ID: 25028379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study.
    Yin R; Cao H; Fu T; Zhang Q; Zhang L; Li L; Gu Z
    Rheumatol Int; 2017 Jul; 37(7):1187-1194. PubMed ID: 28551724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nation-wide population-based cohort study.
    Jatuworapruk K; Grainger R; Dalbeth N; Taylor WJ
    Int J Rheum Dis; 2022 Feb; 25(2):154-162. PubMed ID: 34796661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of Gout in a Hospital Setting: A Lost Opportunity.
    Wright S; Chapman PT; Frampton C; O'Donnell JL; Raja R; Stamp LK
    J Rheumatol; 2017 Oct; 44(10):1493-1498. PubMed ID: 28765252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.